Today: 8 February 2026
Subscribe
Browse Category

NYSE:UNH News 29 January 2026 - 7 February 2026

UnitedHealth stock price ticks up to $276.65 as insurer cost signals shift — what investors watch next week

UnitedHealth stock price ticks up to $276.65 as insurer cost signals shift — what investors watch next week

UnitedHealth shares closed up 3% at $276.65 Friday, rebounding after Molina Healthcare’s weak 2026 outlook rattled managed-care stocks. Centene later issued a stronger 2026 profit forecast, easing some pressure. UnitedHealth traded between $263.00 and $277.74 during the session. Investors await Humana’s results Feb. 11 and a Medicare Advantage rate decision April 6.
7 February 2026
·
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
UnitedHealth (UNH) stock rebounds nearly 2% as sector digests cost shock, Mizuho trims target

UnitedHealth (UNH) stock rebounds nearly 2% as sector digests cost shock, Mizuho trims target

UnitedHealth shares rose 1.9% to $273.79 Friday, rebounding after Molina Healthcare’s weak 2026 profit outlook sent sector stocks tumbling Thursday. Mizuho cut its price target for UnitedHealth to $350 but kept an Outperform rating. Investors await the April 6 CMS decision on 2027 Medicare Advantage rates. Molina shares plunged nearly 28%, while Centene fell 5.5% and Cigna gained about 3%.
6 February 2026
·
UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth shares fell nearly 3% to $275.92 in after-hours trading Wednesday after the FTC announced a 10-year insulin pricing settlement with Cigna’s Express Scripts, increasing scrutiny on OptumRx and CVS Caremark. Investors are watching for an FTC oral argument Feb. 5 and a House hearing on drug prices Feb. 11. CVS and Cigna shares also declined. UnitedHealth did not comment.
5 February 2026
·····
UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth shares rose 1% to $289.75 Monday, outperforming peers as Humana, Elevance, and Cigna declined. Truist and JPMorgan cut price targets but kept positive ratings. Investors focused on Medicare Advantage payment rates and 2026 cost trends after last week’s sector sell-off. Final 2027 Medicare Advantage rates are expected in April.
2 February 2026
·······
UnitedHealth stock: the Medicare Advantage deadline that could drive UNH’s next move

UnitedHealth stock: the Medicare Advantage deadline that could drive UNH’s next move

UnitedHealth Group shares fell 1.8% to $286.93 Friday as investors weighed the government’s proposed 2027 Medicare Advantage rates. The Centers for Medicare & Medicaid Services set a Feb. 25 deadline for comments and plans to announce final rates by April 6. UnitedHealth’s stock had plunged nearly 20% earlier in the week after the initial rate proposal missed analyst expectations.
1 February 2026
·
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
Dow Jones today: Warsh Fed pick and hot inflation data hang over Monday’s open

Dow Jones today: Warsh Fed pick and hot inflation data hang over Monday’s open

The Dow fell 179.09 points, or 0.4%, to 48,892.47 Friday after Trump named Kevin Warsh as his pick for Fed chair and producer inflation came in hotter than expected. Thom Tillis said he would block Warsh’s confirmation until a Justice Department probe into Powell ends. The S&P 500 dropped 0.43%, Nasdaq lost 0.94%. The January U.S. jobs report is due next Friday.
1 February 2026
········
UnitedHealth stock slips again after Barclays trims target — here’s what traders are watching next

UnitedHealth stock slips again after Barclays trims target — here’s what traders are watching next

UnitedHealth shares fell 1.8% to $286.93 in after-hours trading Friday after Barclays cut its price target. The stock has dropped about 18% since Monday, triggered by a 20% plunge Tuesday. UnitedHealth forecast 2026 revenue just over $439 billion, down 2% from last year, and signaled a medical care ratio of 88.8%. Several banks trimmed price targets this week, citing Medicare-related uncertainty.
31 January 2026
·
UnitedHealth stock dips again as Medicare Advantage rate worries hang over UNH shares

UnitedHealth stock dips again as Medicare Advantage rate worries hang over UNH shares

UnitedHealth Group shares fell 2.1% to $286.12 in late-morning trading Friday, extending losses after this week’s selloff. Investors focused on proposed 2027 Medicare Advantage payment changes, with the government’s comment period ending Feb. 25 and final rates due April 6. CMS projects a net average payment increase of 0.09% for 2027. UBS cut its price target for UnitedHealth to $410, citing rate uncertainty.
30 January 2026
·
UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth shares fell 0.6% to $292.29 in after-hours trading Thursday after the U.S. Labor Department proposed new disclosure rules for pharmacy benefit managers. The proposal would require PBMs to reveal fee and compensation details. Investors are also closely watching upcoming Medicare Advantage rate decisions. Related health insurer stocks showed mixed movement late Thursday.
30 January 2026
·····
Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health shares rose 1% to $345.44 Thursday, leading gains in managed-care stocks after policy and earnings volatility. The company forecast 2026 adjusted EPS of at least $25.50, below analyst expectations, and warned of revenue declines amid Medicaid and ACA headwinds. Medicare Advantage payments are set for a minimal 0.09% increase in 2027, rattling the sector. ACA enrollment for 2026 dropped to about 23 million as subsidies ended.
29 January 2026
·····
UnitedHealth stock price today: UNH slips as Medicare Advantage rate shock still bites

UnitedHealth stock price today: UNH slips as Medicare Advantage rate shock still bites

UnitedHealth Group shares fell 1.2% to $290.50 Thursday after regulators proposed a 0.09% Medicare Advantage rate hike for 2027, far below expectations. The company warned of possible benefit cuts and a $1.6 billion charge tied to a cyberattack. UnitedHealth stock plunged 19% Tuesday after executives called the proposal “disappointing.” CMS will issue final rates by April 6.
29 January 2026
·
1 2 3 … 7

Stock Market Today

Texas Instruments stock price slips despite chip rally; what TXN holders watch into Monday

8 February 2026
New York, Feb 7, 2026, 17:30 EST — Market closed. Texas Instruments Inc shares fell 1.13% on Friday to close at $221.44, underperforming a broad market surge and ending the session about 3% below a 52-week high set earlier this week, according to market data. (MarketWatch) The gap was noticeable because chip stocks ripped higher on bets that Big Tech’s new spending targets will feed demand for data-center components, lifting Nvidia, AMD and Broadcom and pushing the PHLX semiconductor index up 5.7%. “This trade has been volatile… but I think there’s enough evidence that there’s real demand for AI products,”
Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop